StoneX Group’s Atossa Therapeutics ATOS Stock Holding History

StoneX Group’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,325	Closed	-$11.7K	–	936
2025 Q4	$11.7K	Buy	+1,325	New	+$16.8K	﹤0.01%	994

Other funds holding ATOS

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

StoneX Group's ATOS Position: Q1 2026 in Review

StoneX Group sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 1,325 shares — an estimated $11.7K sold.

StoneX Group first reported a position in ATOS in Q4 2025 and held it in 1 quarter. The position peaked at $11.7K in Q4 2025. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

StoneX Group reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
StoneX Group sold 1,325 Atossa Therapeutics shares in Q1 2026, an estimated $11.7K.
StoneX Group first reported a position in Atossa Therapeutics in Q4 2025 and held it in 1 quarter.
StoneX Group's Atossa Therapeutics position peaked at $11.7K in Q4 2025.
33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on StoneX Group's 13F filing for Q1 2026, filed 14 May 2026.